Marc de Perrot

Marc de Perrot, MD

Chemo-immunotherapy

The overall goal is to improve the outcome of mesothelioma by combining conventional chemotherapy with immunotherapy in murine mesothelioma models.

Although the first line chemotherapy composed of cisplatin and pemetrexed (Alimta) can prolong survival compared with cisplatin alone, the effect is limited. One neglected issue that has been highlighted is cancer cell repopulation during the intervals of chemotherapy. Evidence has shown that the rate of repopulation of surviving cancer cells accelerates over time. Therefore, novel approaches inhibiting this process need to be developed. Immune suppression is quite common in cancer microenvironments including mesothelioma. We attempt to improve the efficacy of chemotherapy by removing the brake of immunosuppression so as to enhance specific anti-tumour immunity. The immunosuppressive compartments such as regulatory T cells (Treg), or immunoinhibitory molecules such as CTLA-4 and PD-1 can be employed as targets to enhance T cell immune responses.

We have demonstrated that Treg cell depletion between cycles of chemotherapy has resulted in improvement of the anti-tumour effect of chemotherapy. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation between chemotherapy treatments in murine mesothelioma models.
J Thorac Cardiovasc Surg. 2017 Apr 13;:
Ujiie H, Kato T, Hu HP, Patel P, Wada H, Fujino K, Weersink R, Nguyen E, Cypel M, Pierre A, de Perrot M, Darling G, Waddell TK, Keshavjee S, Yasufuku K
Eur J Cardiothorac Surg. 2017 Apr 25;:
Moser B, Fadel E, Fabre D, Keshavjee S, de Perrot M, Thomas P, Brioude G, Van Raemdonck D, Viskens S, Lang-Lazdunski L, Bille A, Weder W, Jungraithmayr W, Ruffini E, Guerrera F, Gómez de Antonio D, Liberman M, Novoa N, Scarci M, Janik S, Klepetko W
Eur Respir J. 2017 Mar;49(3):
de Perrot M, Dong Z, Bradbury P, Patsios D, Keshavjee S, Leighl NB, Hope A, Feld R, Cho J
Stem Cell Reports. 2017 Mar 09;:
Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B
J Thorac Cardiovasc Surg. 2017 Feb 09;:
Czarnecka-Kujawa K, Rochau U, Siebert U, Atenafu E, Darling G, Waddell TK, Pierre A, De Perrot M, Cypel M, Keshavjee S, Yasufuku K
J Thorac Dis. 2017 Feb;9(2):237-239
de Perrot M, Donahoe L
Ann Thorac Surg. 2017 Mar 02;:
Bendzsak A, Waddell TK, Yasufuku K, Keshavjee S, de Perrot M, Cypel M, Pierre AF, Darling GE
Ann Thorac Surg. 2017 Mar 02;:
Donahoe LL, de Valence M, Atenafu EG, Hanna WC, Waddell TK, Pierre AF, Yasufuku K, de Perrot M, Cypel M, Keshavjee S, Darling GE
J Thorac Dis. 2017 Jan;9(1):80-87
Agzarian J, Linkins LA, Schneider L, Hanna WC, Finley CJ, Schieman C, De Perrot M, Crowther M, Douketis J, Shargall Y
J Clin Oncol. 2009 May 20;27(15_suppl):7581
Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho B, De Perrot M, Liu G

Pages


 

Director, Toronto Mesothelioma Research Program
Associate Professor, Surgery, University of Toronto